Harrow Health, Inc. (HROW)

Do Options Traders Know Something About Harrow Stock We Don't?

Harrow (NASDAQ:HROW) Stock Keeps Buy Rating at BTIG Research

Harrow Closes Acquisition of TYRVAYA®

Harrow, Inc. (NASDAQ:HROW) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Harrow (NASDAQ:HROW) Stock Falls 6.8% – Here’s Why

Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)

Harrow to Participate in Three Investor Conferences in September

Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

Harrow Q2 Earnings Call Highlights

Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting